Functional Consequences of the Somatopause and its Treatment

Andrew R. Hoffman, Steven Lieberman, Gail Butterfield, Janice Thompson, Raymond L. Hintz, Gian Paolo Ceda, Robert Marcus

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

Original languageEnglish (US)
Pages (from-to)73-76
Number of pages4
JournalEndocrine
Volume7
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Hormones
Growth Hormone-Releasing Hormone
Hormone Replacement Therapy
Somatomedins
Body Composition
Growth Hormone
Quality of Life
Morbidity
Therapeutics

Keywords

  • Body composition
  • GH
  • IGF-I
  • Somatopause

ASJC Scopus subject areas

  • Endocrinology

Cite this

Hoffman, A. R., Lieberman, S., Butterfield, G., Thompson, J., Hintz, R. L., Ceda, G. P., & Marcus, R. (1997). Functional Consequences of the Somatopause and its Treatment. Endocrine, 7(1), 73-76.

Functional Consequences of the Somatopause and its Treatment. / Hoffman, Andrew R.; Lieberman, Steven; Butterfield, Gail; Thompson, Janice; Hintz, Raymond L.; Ceda, Gian Paolo; Marcus, Robert.

In: Endocrine, Vol. 7, No. 1, 1997, p. 73-76.

Research output: Contribution to journalArticle

Hoffman, AR, Lieberman, S, Butterfield, G, Thompson, J, Hintz, RL, Ceda, GP & Marcus, R 1997, 'Functional Consequences of the Somatopause and its Treatment', Endocrine, vol. 7, no. 1, pp. 73-76.
Hoffman AR, Lieberman S, Butterfield G, Thompson J, Hintz RL, Ceda GP et al. Functional Consequences of the Somatopause and its Treatment. Endocrine. 1997;7(1):73-76.
Hoffman, Andrew R. ; Lieberman, Steven ; Butterfield, Gail ; Thompson, Janice ; Hintz, Raymond L. ; Ceda, Gian Paolo ; Marcus, Robert. / Functional Consequences of the Somatopause and its Treatment. In: Endocrine. 1997 ; Vol. 7, No. 1. pp. 73-76.
@article{a27df97930344764aee556309d02018a,
title = "Functional Consequences of the Somatopause and its Treatment",
abstract = "The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.",
keywords = "Body composition, GH, IGF-I, Somatopause",
author = "Hoffman, {Andrew R.} and Steven Lieberman and Gail Butterfield and Janice Thompson and Hintz, {Raymond L.} and Ceda, {Gian Paolo} and Robert Marcus",
year = "1997",
language = "English (US)",
volume = "7",
pages = "73--76",
journal = "Endocrine",
issn = "0969-711X",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Functional Consequences of the Somatopause and its Treatment

AU - Hoffman, Andrew R.

AU - Lieberman, Steven

AU - Butterfield, Gail

AU - Thompson, Janice

AU - Hintz, Raymond L.

AU - Ceda, Gian Paolo

AU - Marcus, Robert

PY - 1997

Y1 - 1997

N2 - The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

AB - The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

KW - Body composition

KW - GH

KW - IGF-I

KW - Somatopause

UR - http://www.scopus.com/inward/record.url?scp=0031196695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031196695&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 73

EP - 76

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 1

ER -